title: Controlled trial of antilymphocyte globulin in cadaveric transplantation.
abstract: Since January 1974, alternate cadaveric renal transplants were treated with antilymphocyte globulin (Behringwerke) om addotopm to prednisone and azathioprine. Thirty patients were treated in this way. 53% of patients receiving ALG had a functioning graft at six months as opposed to 40% in the control group. This difference is not significant. All other parameters were approximately equal in the two groups. No serious side effects of ALG treatment were observed.
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D002986:Clinical Trials as Topic; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation; D008231:Lymphopenia / Q000139:chemically induced; D014181:Transplantation Immunology
chemical_list: D000961:Antilymphocyte Serum